Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash.

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial ...

After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 ...

The question of whether thinking alone proves existence or if existence encompasses more than thought takes us into the nature of Being, self-awareness, and life. Rene Descartes ' Cogito, ergo sum ...

Updated Phase 2a Open-Label Trial Results Cartesian today also announced positive updated results from retreated participants enrolled in the Phase 2a open-label portion of the trial.

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial ...

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit ...

RENÉ DESCARTES (1596–1650), philosopher and mathematician, is of course universally, regarded as the inventor of the method of co-ordinates in geometry; hence the common name for them ...

EVERYBODY knows at least one joke about René Descartes, even if it is only the one about the philosopher who walks into a bar. “You’ll have the usual?” the barman asks. “I think not,” says Descartes, ...

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first patient has been dosed in its phase 2 open-label ...